Prime Medicine, Inc. Common Stock (PRME) is a publicly traded Healthcare sector company. As of May 21, 2026, PRME trades at $2.81 with a market cap of $507.54M and a P/E ratio of -2.08. PRME moved +0.00% today. Year to date, PRME is -20.73%; over the trailing twelve months it is +140.85%. Its 52-week range spans $1.11 to $6.94. Analyst consensus is strong buy with an average price target of $7.80. Rallies surfaces PRME's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Prime Medicine Secures $149.2M Cash Into 2027, Eyes Two IND Filings: Prime Medicine ended Q1 2026 with $149.2 million cash runway into 2027, reporting a $49.1 million net loss as R&D expenses fell to $34.1 million. The company plans IND/CTA filings for PM577 in Wilson Disease H1 2026 and PM647 mid-2026, with initial clinical data expected in 2027.
| Metric | Value |
|---|---|
| Price | $2.81 |
| Market Cap | $507.54M |
| P/E Ratio | -2.08 |
| EPS | $-1.35 |
| Dividend Yield | 0.80% |
| 52-Week High | $6.94 |
| 52-Week Low | $1.11 |
| Volume | 79.85K |
| Avg Volume | 0 |
| Revenue (TTM) | $4.63M |
| Net Income | $-201.14M |
| Gross Margin | 0.00% |
8 analysts cover PRME: 0 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.80.